Canagliflozin: A Comprehensive Review of Advances in Preclinical Research

卡格列净 医学 临床前研究 医学物理学 内分泌学 糖尿病 2型糖尿病
作者
Bushra Imran,Farogh Ahsan,Tarique Mahmood,Mohd Masih Uzzaman Khan,Shahzadi Bano,Syed Mehdi Hasan Zaidi,Jamal Akhtar Ansari,Aditya Singh
出处
期刊:Drug research [Thieme Medical Publishers (Germany)]
卷期号:75 (06): 183-201 被引量:2
标识
DOI:10.1055/a-2577-1899
摘要

Abstract Canagliflozin is a synthetic sodium glucose transporter inhibitor (SGLT2i). It is the latest approved class of medicine used in the treatment of type 2 diabetes mellitus. As diabetes is emerging as the most common metabolic disorder, SGLT2i has lightened up the path of treatment with additional benefits. SGLT2 is located in the proximal convoluted tubules of the nephron and is responsible for glucose reabsorption. Thus, inhibiting the SGLT2 leads to a decline in glucose concentration in the plasma. The secondary effects of canagliflozin, such as cardiac protection, renoprotective, and decreased obesity, have made it more putative in the treatment of diabetes mellitus. There are some side effects of canagliflozin, such as volume depletion, genital and urinary tract infection, and lower limb amputation, which could be a matter of concern for patients. Being an anti-diabetic drug, canagliflozin also possesses anti-inflammatory and anti-cancer properties. Several studies have been conducted to determine the efficacy of canagliflozin as an anti-cancer agent. Its pharmacokinetics indicate rapid absorption, reaching peak plasma concentrations within 1–2 hours. With a half-life of approximately 12 hours, it undergoes minimal hepatic metabolism and is primarily excreted unchanged via urine. Common adverse drug reactions (ADRs) include urinary tract infections and dehydration. Clinical trials on canagliflozin, both alone and in combination with other diabetes complications, have been conducted, with some completed and others in various phases. This review article contains information about the pharmacokinetics, drug safety, and efficacy profile of canagliflozin, along with details regarding toxicological studies of canagliflozin.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
小名完成签到 ,获得积分10
1秒前
霖29发布了新的文献求助10
2秒前
4秒前
行走发布了新的文献求助10
5秒前
心若向阳完成签到,获得积分10
5秒前
yuuuuuuuuuuu发布了新的文献求助10
9秒前
恒驰完成签到,获得积分20
10秒前
霖29完成签到,获得积分10
10秒前
Luis完成签到,获得积分10
11秒前
yibo2026完成签到 ,获得积分10
11秒前
梦安完成签到 ,获得积分10
11秒前
Austin完成签到,获得积分10
11秒前
科研通AI2S的应助被LY采纳,获得10
12秒前
14秒前
隐形曼青的应助被xiaolizi采纳,获得30
17秒前
英姑的应助被li采纳,获得10
18秒前
文艺的访曼完成签到,获得积分10
19秒前
聪慧板凳完成签到,获得积分10
19秒前
自然的峰单完成签到,获得积分10
21秒前
里奥完成签到 ,获得积分10
22秒前
李健的应助被533采纳,获得10
23秒前
大意的初夏完成签到,获得积分10
25秒前
27秒前
chensiying完成签到 ,获得积分10
30秒前
情怀的应助被yuuuuuuuuuuu采纳,获得10
34秒前
35秒前
Tonald Yang发布了新的文献求助10
37秒前
rick3455完成签到,获得积分10
39秒前
愚者完成签到,获得积分10
41秒前
Jack_20708124完成签到 ,获得积分10
41秒前
涂鸦少年完成签到 ,获得积分10
49秒前
huluwa完成签到,获得积分10
51秒前
sa完成签到 ,获得积分10
55秒前
orixero的应助被叶问采纳,获得10
57秒前
离大谱完成签到,获得积分10
58秒前
端庄沉鱼完成签到,获得积分10
1分钟前
小名完成签到 ,获得积分10
1分钟前
1分钟前
zt完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190389
求助须知:如何正确求助?哪些是违规求助? 9577468
关于积分的说明 21852640
捐赠科研通 7789048
什么是DOI,文献DOI怎么找? 3436369
关于科研通互助平台的介绍 2560180
邀请新用户注册赠送积分活动 2483012